Background Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used
as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as …

Objective: To evaluate the efficacy and toxicity of methotrexate (MTX) monotherapy
compared with MTX combination with non-biological disease-modifying antirheumatic drugs (…

Objective To summarize the potential predictors of remission in patients with rheumatoid
arthritis (RA). Methods We performed a systematic review of prognostic studies that identified …

Background The availability of increasing numbers of biological agents for the treatment of
rheumatoid arthritis (RA) offers several therapeutic options. While all biologicals have proven …

Objective. To perform a systematic review of the benefits and harms of folic acid and folinic
acid in reducing the mucosal, gastrointestinal, hepatic, and hematologic side effects of …

Background Methotrexate (MTX) is among the most effective disease modifying anti‐rheumatic
drugs (DMARDs) in rheumatoid arthritis (RA) with less toxicity and better tolerability. …

Background There are conflicting and inconsistent data regarding the gastrointestinal (GI)
protective effect of cyclooxygenase-2 (COX-2) inhibitors and of non-steroidal anti-inflammatory …

The objective of this study was to investigate the association of rheumatoid factor (RF) and
anti-citrullinated peptide antibodies (ACPA) status with disease progression and treatment …

Background Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that
primarily affects joints with some extraarticular involvement. If inappropriately treated, it usually …

Background Several literatures reported that highly selective cycloxygenase-2 inhibitors (COX-2
inhibitors) had no effect on platelet function. However, some experts suggested …